

**Insert for AmpC Confirm Kit**

REVISION:  
DATE OF ISSUE:  
LANGUAGE:

DBV0031F  
15/03-2013  
English

**AmpC Confirm Kit**

FOR IN VITRO DIAGNOSTIC USE ONLY

- PRODUCT GROUP:** Kits for beta lactamase identification
- MANUFACTURER:** ROSCO Diagnostica A/S, Taastrupgaardsvej 30, DK-2630 Taastrup, Denmark.
- INTENDED USE:** Tablets are used for *in vitro* identification of microbial resistance mechanisms by the agar tablet/disc diffusion method, in order to confirm the mechanism by which the organism has gained resistance to specific antimicrobial agents.
- INTENDED USERS:** Only to be used by professionals and people trained to work with microbes and disc diffusion testing.
- DETAILED INSTRUCTIONS:** ROSCO's detailed Instruction for Use for *Detection of resistance* mechanisms should be available in each laboratory working with ROSCO's *Diagnostic products*. Last edition of Instruction for Use can be seen in and/or printed out from ROSCO's website [www.rosco.dk](http://www.rosco.dk). Here more detailed information can also be found in ROSCO's User's Guide for *Detection of resistance mechanisms*. Instructions for Use and User's Guide can be obtained free of charge from your local distributor on request, or from ROSCO Diagnostica A/S:  
E-mail: [info@rosco.dk](mailto:info@rosco.dk) or  
Fax: +45 43 52 73 74
- PRINCIPLE OF THE TEST:** This Kit consists of four cartridges of disc diffusion tablets: one cartridge of tablets with Cefotaxime, one with Ceftazidime and two cartridges of the cephalosporins combined with Cloxacillin (AmpC inhibitor). If an organism is suspected of AmpC activity it can be shown by a difference in the inhibition zone of the cephalosporin(s) alone and in combination with the inhibitor.
- CONTENT AND FORMULATION:**
- 4 cartridges, formulated for maximum stability, each containing approximately 50 tablets:
  - 1 Cefotaxime 30 µg, coded CTX30
  - 2 Cefotaxime 30 µg + Cloxacillin, coded CTXCX
  - 3 Ceftazidime 30 µg, coded CAZ30
  - 4 Ceftazidime 30 µg + Cloxacillin, coded CAZCX
- STORAGE/HANDLING:** Store at 2-8°C in the box provided or unopened cartridges until the expiry date shown on the product label. Allow the cartridges to acclimatize to room temperature for 30-60 minutes before the lid is removed from the cartridge. Once a cartridge has been opened and in particular when placed in a dispenser, it should be kept at room temperature for up to 2 months. If necessary, when in use for a longer period than 2 months, the cartridges can be stored at 2-8°C. Always seal the cartridges with the original green lid, and never place a dispenser in the refrigerator. When stored at 2-8°C the cartridges should be allowed to acclimatize, as described above, before use.
- PRECAUTIONS:** For *in vitro* diagnostic use only. Safety precautions should be taken and aseptic techniques used when working with potential biohazards. To be used only by adequately trained and qualified laboratory personnel. Sterilize all biohazard waste before disposal. Refer to Product Safety Data Sheet.

**MATERIALS REQUIRED BUT NOT PROVIDED:**

Standard microbial equipment such as loops, culture media, incubator etc. and biochemical reagents.

**PROCEDURE:**

1. Using a fresh, pure culture prepare a suspension of the organism to be tested equivalent to McFarland 0.5
2. Using a sterile swap or Drigalski spatula spread the suspension uniformly over the entire area of a Mueller Hinton susceptibility agar plate.
3. Using a single tablet dispenser, place one of each tablet on the inoculated agar plate, ensuring sufficient space between individual tablets to allow for proper measurement of inhibition zones. Notice that more than one Confirm Kit can be tested on the same plate.
4. Incubate at 35±1°C for 18±2 hours (overnight)
5. Measure and record the diameter of the inhibition zone. No zone around a tablet corresponds to a 9 mm inhibition zone.

**INTERPRETATION OF RESULTS:**

The results are interpreted by comparing the inhibition zones of the different tablets.

1. Compare the zone of inhibition of Cefotaxime 30 µg and Ceftazidime 30 µg tablet to the zones of inhibition of Cefotaxime 30 µg + Cloxacillin and Ceftazidime 30 µg + Cloxacillin tablets, respectively. If these zones are within 3mm of each other, record the organism as not expressing AmpC activity.
2. Measure the inhibition zones around Cefotaxime 30 µg + Cloxacillin (CTXCX) and Ceftazidime 30 µg + Cloxacillin (CAZCX), and compare with the respective zones around Cefotaxime 30 µg (CTX30) and Ceftazidime 30 µg (CAZ30). If one or both of the combination discs show zones ≥ 5mm than the single discs the organism is demonstrating AmpC activity.
3. Use Table 1 to assist in the interpretation

**QUALITY CONTROL:**

Although ROSCO Diagnostica A/S produces the, by far, most stable diffusion discs (tablets) it is necessary to perform regular quality control. This should be done with at least one organism to demonstrate a positive reaction and at least one organism to demonstrate a negative reaction. Zones of inhibition obtained using the combination tablets plus the cephalosporin alone tablet against the negative control (i.e. *E. coli* ATCC 25922), should be within 3 mm. Any greater difference indicates that the product has lost activity and should not be used.

*As positive Q. C. stains the following may be used:*  
*Enterobacter cloacae* NCTC 13406, AmpC positive  
*Enterobacter cloacae* ATCC BAA – 1143, Amp C positive  
*E. coli* ATCC 25922 is a negative *Q. C. stain*

**Table 1**

		<b>Cefotaxime 30 µg CTX30</b>	<b>Ceftazidime 30 µg CAZ30</b>
<b>AmpC</b>	<b>CTXCX</b>	≥ 5mm	-
<b>AmpC</b>	<b>CAZCX</b>	-	≥ 5mm

No AmpC activity: All zones in the combinations within 2 mm of the corresponding single agents.

Note: “-“ means that the difference is irrelevant (i.e. CTXCX should not be compared with CAZ30 for the detection of AmpC)

REFERENCES:

[www.rosco.dk](http://www.rosco.dk)